Editorial
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Nov 15, 2021; 13(11): 1544-1550
Published online Nov 15, 2021. doi: 10.4251/wjgo.v13.i11.1544
Inhibition of poly (ADP-Ribose) polymerase: A promising strategy targeting pancreatic cancer with BRCAness phenotype
Keun-Yeong Jeong, Haejun Lee
Keun-Yeong Jeong, R&D Center, Metimedi Pharmaceuticals, Incheon 22006, South Korea
Haejun Lee, Department of Nuclear Medicine, Gil Medical Center, Incheon 21565, South Korea
Author contributions: Jeong KY conceived the contents and drafted the manuscript; Jeong KY and Lee H revised the manuscript; and all authors approved the final version of the article.
Conflict-of-interest statement: We have no conflict of interest to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Keun-Yeong Jeong, PhD, Executive Vice President, Research Assistant Professor, R&D Center, Metimedi Pharmaceuticals, 263 Central ro, Incheon 22006, South Korea. alvirus@naver.com
Received: March 17, 2021
Peer-review started: March 17, 2021
First decision: April 19, 2021
Revised: April 20, 2021
Accepted: September 10, 2021
Article in press: September 10, 2021
Published online: November 15, 2021
Processing time: 239 Days and 22.9 Hours
Core Tip

Core Tip: The incidence of germline mutations of the breast cancer susceptibility gene (BRCA), defined as BRCAness, that can be targeted for pancreatic cancer is 9%-17%. Mutations in BRCAs are responsible for causing genetic instability and worsening the prognosis. Therefore, inhibition of poly (ADP-Ribose) polymerase-1 has emerged as a promising therapeutic target for BRCAness pancreatic cancer within the framework of an increase in genome instability.